SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Roader who wrote (688)4/18/1997 3:14:00 PM
From: James Silverman   of 1762
 
Roader,
If you look closely at the insider sales: they sold a month and a half ago at prices up to $30 a share. I don't think that 3 insiders selling then and at those prices had anything to do with the sharp decline. More likely the ML partners 500,000+ shares and SKB selling well over 1M shares on the open market spurred the rapid decline. There aren't that many biotechs that could hold up in the face of that kind of selling into a weak market. The decline was probably further led by weak shareholders imagining the worst as the stock dropped.

The only way I see this stock hitting your $10 target is if some very bad clinical news hits. Other than that forget it, I believe the SKB and ML sales must be very close to winding down.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News